SLN
Silence Therapeutics Plc Health Care Pharmaceutical Preparations Russell 3000
$19.75Close
$2.8BMarket cap
$4.30 – $19.8052-week range
Nov 5, 2026Next report
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 99 · stronger than 99% of stocks over 12 months
- RS line at a 1-year high outperforming the S&P 500 more than at any point this year
- Near its high at its 52-week high
- Accumulation up-day volume 4.0× down-day volume over 50 sessions
Cautions
- Extended 12.0 ATR above its 50-day average
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
0%
1wk
up 0.4%
price change
1mo
up 80.7%
price change
12-month return
up 170%
market up 11% ·
its own up 162%
F-score
3 / 9
Weak
Altman Z
16.97
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
44.9×
price / book
Earnings yield
down 3.3%
EBIT / enterprise value
Cheaper than
12%
of the market · expensive
Revenue growth
down 99%
year on year
EPS growth
—
latest quarter
Sales growth
down 100%
latest quarter · -297 pts
ROE
down 90%
return on equity
Free cash margin
down 11150%
-$62.3M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- profitability slipped from last year
- short-term liquidity weakened
- gross margin narrowed
- assets working less efficiently
- profits backed by cash
- reduced long-term debt
- no new shares issued
Trade setup
ATR%
3.9%
$0.76 a day · 2×ATR $18.22
RS
99 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.2×
vs 50-day average
Up/down volume
3.98
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Gross margin narrowing Gross margin fell from 72.7% to 61.5%. The company is keeping less of each dollar of sales than it did a year ago.
- Revenue shrinking Revenue fell 98.7% over the year, from $43.3M to $559,000.
Last reported
Aug 10, 2026
Results reaction
Aug 10, 2026+24% vs market2 sessions after results
Financials
- Gross 62%
- Net -15852%
- Free cash -11150%
- Cash
- Long-term debt
| FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $21.7M | $31.6M | $43.3M | $559,000 |
| Gross margin | 38% | 59% | 73% | 62% |
| Operating income | -$61.0M | -$64.4M | -$63.3M | -$91.1M |
| Net income | -$50.3M | -$54.2M | -$45.3M | -$88.6M |
| Net margin | -232% | -171% | -105% | -15852% |
| Earnings per share | -$0.52 | -$0.49 | -$0.33 | -$0.63 |
| Free cash flow | -$57.2M | -$49.5M | -$67.9M | -$62.3M |
| Free cash margin | -264% | -156% | -157% | -11150% |
| Cash | — | $68.8M | $121.3M | $11.3M |
| Shareholders' equity | $27.2M | $22.0M | $134.0M | $62.3M |
| Shares outstanding | 107.81m | 118.85m | 141.67m | 141.70m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 10, 2026 | Quarterly ↗ | Jun 30, 2026 | 41d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 5, 2026 | Annual ↗ | Dec 31, 2025 | 64d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Mar 13, 2024 | Annual ↗ | — | 0d |
| Mar 15, 2023 | Annual ↗ | — | 0d |
| Mar 17, 2022 | Annual ↗ | — | 0d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 19, 2026 | Material agreement · Regulation FD ↗ |
| Aug 12, 2026 | Material agreement · Other events ↗ |
| Aug 10, 2026 | Regulation FD · Other events ↗ |
| Aug 10, 2026 | Results ↗ |
| Jun 23, 2026 | Regulation FD ↗ |
| Jun 16, 2026 | Shareholder vote ↗ |
| Jun 11, 2026 | Other events ↗ |
| May 18, 2026 | Material agreement · Agreement ended · Other events ↗ |
| May 7, 2026 | Results ↗ |
| Mar 5, 2026 | Results · Regulation FD ↗ |
| Dec 22, 2025 | Director or officer change ↗ |
| Dec 15, 2025 | Director or officer change · Regulation FD ↗ |